Home / CXCL13/BLC/BCA-1 / Recombinant Human CXCL13/BLC/BCA-1 Protein

Recombinant Human CXCL13/BLC/BCA-1 Protein

Catalog #: 801-CX
20 Citations Datasheet

Carrier Free

Catalog # Availability Size / Price Qty
801-CX-025/CF

With Carrier

Catalog # Availability Size / Price Qty
801-CX-025
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (20)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human CXCL13/BLC/BCA-1 Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR5. The ED50 for this effect is 0.005‑0.02 µg/mL.
Source
E. coli-derived human CXCL13/BLC/BCA-1 protein
Val23-Arg94
Accession #
Q53X90
N-terminal Sequence
Analysis
Val23
Predicted Molecular Mass
8.7 kDa
SDS-PAGE
9 kDa, reducing conditions

Product Datasheets

You must select a language.

x

801-CX (with carrier)

Product Datasheet

You must select a language.

x

801-CX/CF (carrier free)

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

801-CX

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 25 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

801-CX/CF

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL13/BLC/BCA-1

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

References
  1. Gunn, M.D. et al. (1998) Nature, 391:799.
  2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
  3. Forster, R. et al. (1996) Cell 87:1037.
Entrez Gene IDs
10563 (Human); 55985 (Mouse)
Alternate Names
ANGIE; ANGIE2; B cell-attracting chemokine 1; B lymphocyte chemoattractant; BCA1; BCA-1; BCA1B-cell chemoattractant; BCA-1CXC chemokine BLC; B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1); BLC; BLCSmall-inducible cytokine B13; BLR1L; B-lymphocyte chemoattractant; chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); chemokine (C-X-C motif) ligand 13; C-X-C motif chemokine 13; CXCL13; SCYB13; SCYB13B-cell-attracting chemokine 1; small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Citations for Recombinant Human CXCL13/BLC/BCA-1 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

20 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. CXC chemokine ligand-13 promotes metastasis via CXCR5-dependent signaling pathway in non-small cell lung cancer
    Authors: CC Chao, WF Lee, SW Wang, PC Chen, A Yamamoto, TM Chang, SL Weng, JF Liu
    Journal of Cellular and Molecular Medicine, 2021-08-24;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
    Authors: D Biasci, M Smoragiewi, CM Connell, Z Wang, Y Gao, JED Thaventhir, B Basu, L Magiera, TI Johnson, L Bax, A Gopinathan, C Isherwood, FA Gallagher, M Pawula, I Hudecova, D Gale, N Rosenfeld, P Barmpounak, EC Popa, R Brais, E Godfrey, F Mir, FM Richards, DT Fearon, T Janowitz, DI Jodrell
    Proc Natl Acad Sci U S A, 2020-10-30;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis
    Authors: A Ardain, R Domingo-Go, S Das, SW Kazer, NC Howard, A Singh, M Ahmed, S Nhamoyebon, J Rangel-Mor, P Ogongo, L Lu, D Ramsuran, M de la Luz, T K Ulland, M Darby, E Park, F Karim, L Melocchi, R Madansein, KJ Dullabh, M Dunlap, N Marin-Agud, T Ebihara, T Ndung'u, D Kaushal, AS Pym, JK Kolls, A Steyn, J Zúñiga, W Horsnell, WM Yokoyama, AK Shalek, HN Kløverpris, M Colonna, A Leslie, SA Khader
    Nature, 2019-06-05;570(7762):528-532.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis
    Authors: LW Middleton, Z Shen, S Varma, AS Pollack, X Gong, S Zhu, C Zhu, JW Foley, S Vennam, RT Sweeney, K Tu, J Biscocho, O Eminaga, R Nolley, R Tibshirani, JD Brooks, RB West, JR Pollack
    JCI Insight, 2019-05-16;5(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter's Transformation
    Authors: SD Reiff, R Mantel, LL Smith, JT Greene, EM Muhowski, CA Fabian, VM Goettl, M Tran, B Harrington, KA Rogers, FT Awan, K Maddocks, L Andritsos, AM Lehman, D Sampath, R Lapalombel, S Eathiraj, G Abbadessa, B Schwartz, A Johnson, JC Byrd, JA Woyach
    Cancer Discov, 2018-08-09;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis
    Authors: E Armas-Gonz, MJ Domínguez-, A Díaz-Martí, M Arce-Franc, J Castro-Her, G Danelon, V Hernández-, S Bustabad-R, A Cantabrana, M Uguccioni, F Díaz-Gonzá
    Arthritis Res. Ther., 2018-06-07;20(1):114.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. BTKCys481Serdrives ibrutinib resistance via ERK1/2, and protects BTKWild-TypeMYD88 mutated cells by a paracrine mechanism
    Authors: JG Chen, X Liu, M Munshi, L Xu, N Tsakmaklis, MG Demos, A Kofides, ML Guerrera, GG Chan, CJ Patterson, KE Meid, J Gustine, T Dubeau, P Severns, JJ Castillo, ZR Hunter, J Wang, SJ Buhrlage, NS Gray, SP Treon, G Yang
    Blood, 2018-03-01;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120.
    Authors: Blackburn M, Zhong-Min M, Caccuri F, McKinnon K, Schifanella L, Guan Y, Gorini G, Venzon D, Fenizia C, Binello N, Gordon S, Miller C, Franchini G, Vaccari M
    J Immunol, 2015-08-21;195(7):3227-36.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection.
    Authors: Boswell K, Paris R, Boritz E, Ambrozak D, Yamamoto T, Darko S, Wloka K, Wheatley A, Narpala S, McDermott A, Roederer M, Haubrich R, Connors M, Ake J, Douek D, Kim J, Petrovas C, Koup R
    PLoS Pathog, 2014-01-30;10(1):e1003853.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012-07-26;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Authors: Ponader S, Chen SS, Buggy JJ
    Blood, 2011-12-16;119(5):1182-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells.
    Authors: Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van Evercooren A, Couraud P, Cazaubon S
    J Neuroimmunol, 2010-04-18;223(1):131-4.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia.
    Authors: Berrih-Aknin S, Ruhlmann N, Bismuth J, Cizeron-Clairac G, Zelman E, Shachar I, Dartevelle P, de Rosbo NK, Le Panse R
    Ann. Neurol., 2009-10-01;66(4):521-31.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein-Barr virus infection.
    Authors: Ehlin-Henriksson B, Liang W, Cagigi A, Mowafi F, Klein G, Nilsson A
    Immunology, 2009-08-01;127(4):549-57.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis.
    Authors: Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F
    Blood, 2008-06-12;112(5):1620-7.
    Applications: Antibody Absorption
  16. Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue.
    Authors: Lim HW, Kim CH
    J. Immunol., 2007-12-01;179(11):7448-56.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
    Authors: Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA
    Blood, 2007-07-25;110(9):3316-25.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.
    Authors: Lisignoli G, Cristino S, Piacentini A, Cavallo C, Caplan AI, Facchini A
    J. Cell. Physiol., 2006-05-01;207(2):364-73.
    Applications: ELISA (Standard)
  19. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13.
    Authors: Perrier P, Martinez FO, Locati M, Bianchi G, Nebuloni M, Vago G, Bazzoni F, Sozzani S, Allavena P, Mantovani A
    J. Immunol., 2004-06-01;172(11):7031-42.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Expression of functional CCR and CXCR chemokine receptors in podocytes.
    Authors: Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H
    J. Immunol., 2002-06-15;168(12):6244-52.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human CXCL13/BLC/BCA-1 Protein

There are currently no reviews for this product. Be the first to review Recombinant Human CXCL13/BLC/BCA-1 Protein and earn rewards!

Have you used Recombinant Human CXCL13/BLC/BCA-1 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review